pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease
Otsuka Beijing Research
Otsuka Beijing Research Institute
Otsuka Beijing Research clinical programs — 12 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Programs
- 33
- Drugs
- 25
- Patents
- 0
Otsuka Beijing Research projects
12 ClinicalTrials.gov programs sponsored by Otsuka Beijing Research.
Otsuka Beijing Research has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
156-201-00307
Otsuka Beijing Research Institute
Autosomal Recessive Polycystic Kidney Disease
1 trial -
20-AVP-786-306
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
AVP-786 matching placebo, AVP-786
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
Aripiprazole
Otsuka Beijing Research Institute
Bipolar I
1 trial -
Aripiprazole IM Depot
Otsuka Beijing Research Institute
Schizophrenia
1 trial -
Delamanid + OBR
Otsuka Beijing Research Institute
Multidrug-resistant Tuberculosis
1 trial -
Escitalopram
Otsuka Beijing Research Institute
Major Depressive Disorder (MDD)
1 trial -
JNT517-301
Otsuka Beijing Research Institute
Phenylketonuria
1 trial -
Sibeprenlimab 400 mg
Otsuka Beijing Research Institute
Immunoglobulin A Nephropathy
1 trial -
Sibeprenlimab 400 mg s.c. Q4weeks
Otsuka Beijing Research Institute
Immunoglobulin A Nephropathy
1 trial -
Tolvaptan
Otsuka Beijing Research Institute
Cardiac Edema
1 trial -
Tolvaptan
Otsuka Beijing Research Institute
Autosomal Recessive Polycystic Kidney Disease
1 trial
Frequently asked questions
How many clinical projects does Otsuka Beijing Research have?
12 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.